nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—MAP3K3—esophageal cancer	0.681	1	CbGaD
Ruxolitinib—PRKG2—smooth muscle tissue—esophageal cancer	0.00219	0.02	CbGeAlD
Ruxolitinib—JAK1—neck—esophageal cancer	0.00192	0.0175	CbGeAlD
Ruxolitinib—PRKG2—digestive system—esophageal cancer	0.00173	0.0158	CbGeAlD
Ruxolitinib—PLK3—bronchus—esophageal cancer	0.00168	0.0153	CbGeAlD
Ruxolitinib—PLK1—digestive system—esophageal cancer	0.00155	0.0142	CbGeAlD
Ruxolitinib—PLK3—trachea—esophageal cancer	0.00151	0.0137	CbGeAlD
Ruxolitinib—PRKG2—lung—esophageal cancer	0.00145	0.0132	CbGeAlD
Ruxolitinib—BMP2K—neck—esophageal cancer	0.00144	0.0131	CbGeAlD
Ruxolitinib—PRKCE—lung—esophageal cancer	0.00135	0.0123	CbGeAlD
Ruxolitinib—JAK1—epithelium—esophageal cancer	0.00131	0.0119	CbGeAlD
Ruxolitinib—PLK1—lung—esophageal cancer	0.0013	0.0118	CbGeAlD
Ruxolitinib—RPS6KA6—lung—esophageal cancer	0.0013	0.0118	CbGeAlD
Ruxolitinib—JAK1—bronchus—esophageal cancer	0.00129	0.0117	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—esophageal cancer	0.00126	0.0115	CbGeAlD
Ruxolitinib—CAMK1D—bronchus—esophageal cancer	0.00126	0.0115	CbGeAlD
Ruxolitinib—DAPK2—bronchus—esophageal cancer	0.00123	0.0112	CbGeAlD
Ruxolitinib—RET—neck—esophageal cancer	0.00122	0.0111	CbGeAlD
Ruxolitinib—MARK2—digestive system—esophageal cancer	0.00118	0.0107	CbGeAlD
Ruxolitinib—JAK1—trachea—esophageal cancer	0.00116	0.0105	CbGeAlD
Ruxolitinib—DCLK1—trachea—esophageal cancer	0.00116	0.0105	CbGeAlD
Ruxolitinib—DAPK3—bronchus—esophageal cancer	0.00116	0.0105	CbGeAlD
Ruxolitinib—CLK2—bronchus—esophageal cancer	0.00114	0.0104	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—esophageal cancer	0.00113	0.0103	CbGeAlD
Ruxolitinib—CAMK1D—trachea—esophageal cancer	0.00113	0.0103	CbGeAlD
Ruxolitinib—ROCK1—epithelium—esophageal cancer	0.00113	0.0103	CbGeAlD
Ruxolitinib—DAPK2—trachea—esophageal cancer	0.0011	0.01	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—esophageal cancer	0.00109	0.00988	CbGeAlD
Ruxolitinib—PLK3—lung—esophageal cancer	0.00108	0.00987	CbGeAlD
Ruxolitinib—BMPR2—bronchus—esophageal cancer	0.00108	0.00981	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—esophageal cancer	0.00105	0.0096	CbGeAlD
Ruxolitinib—LTK—lung—esophageal cancer	0.00105	0.00953	CbGeAlD
Ruxolitinib—CLK2—trachea—esophageal cancer	0.00103	0.00936	CbGeAlD
Ruxolitinib—CAMK1—lung—esophageal cancer	0.00101	0.00923	CbGeAlD
Ruxolitinib—JAK3—digestive system—esophageal cancer	0.001	0.00912	CbGeAlD
Ruxolitinib—JAK1—digestive system—esophageal cancer	0.000995	0.00906	CbGeAlD
Ruxolitinib—DCLK1—digestive system—esophageal cancer	0.000995	0.00906	CbGeAlD
Ruxolitinib—MARK2—lung—esophageal cancer	0.000983	0.00896	CbGeAlD
Ruxolitinib—BMP2K—bronchus—esophageal cancer	0.000964	0.00878	CbGeAlD
Ruxolitinib—STK16—digestive system—esophageal cancer	0.000934	0.00851	CbGeAlD
Ruxolitinib—HIPK2—digestive system—esophageal cancer	0.000929	0.00846	CbGeAlD
Ruxolitinib—NUAK2—trachea—esophageal cancer	0.000925	0.00842	CbGeAlD
Ruxolitinib—PRKCE—lymph node—esophageal cancer	0.000924	0.00841	CbGeAlD
Ruxolitinib—TAOK2—lung—esophageal cancer	0.00091	0.00829	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—esophageal cancer	0.000888	0.00808	CbGeAlD
Ruxolitinib—PLK1—lymph node—esophageal cancer	0.000888	0.00808	CbGeAlD
Ruxolitinib—MAP3K7—bronchus—esophageal cancer	0.000867	0.0079	CbGeAlD
Ruxolitinib—ROCK1—digestive system—esophageal cancer	0.000857	0.0078	CbGeAlD
Ruxolitinib—MKNK2—epithelium—esophageal cancer	0.000854	0.00777	CbGeAlD
Ruxolitinib—TYK2—bronchus—esophageal cancer	0.000852	0.00776	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—esophageal cancer	0.000849	0.00773	CbGeAlD
Ruxolitinib—MKNK2—bronchus—esophageal cancer	0.000841	0.00766	CbGeAlD
Ruxolitinib—IRAK1—bronchus—esophageal cancer	0.000841	0.00766	CbGeAlD
Ruxolitinib—JAK3—lung—esophageal cancer	0.000836	0.00762	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—esophageal cancer	0.000833	0.00759	CbGeAlD
Ruxolitinib—RET—epithelium—esophageal cancer	0.000832	0.00758	CbGeAlD
Ruxolitinib—BMPR2—digestive system—esophageal cancer	0.000832	0.00758	CbGeAlD
Ruxolitinib—JAK1—lung—esophageal cancer	0.000831	0.00757	CbGeAlD
Ruxolitinib—DCLK1—lung—esophageal cancer	0.000831	0.00757	CbGeAlD
Ruxolitinib—PLK4—lung—esophageal cancer	0.000826	0.00752	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—esophageal cancer	0.000822	0.00749	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—esophageal cancer	0.000822	0.00749	CbGeAlD
Ruxolitinib—CAMK1D—lung—esophageal cancer	0.000811	0.00739	CbGeAlD
Ruxolitinib—PHKG2—lung—esophageal cancer	0.000806	0.00734	CbGeAlD
Ruxolitinib—DAPK2—lung—esophageal cancer	0.000793	0.00722	CbGeAlD
Ruxolitinib—JAK2—epithelium—esophageal cancer	0.000787	0.00717	CbGeAlD
Ruxolitinib—STK16—lung—esophageal cancer	0.00078	0.0071	CbGeAlD
Ruxolitinib—MAP3K7—trachea—esophageal cancer	0.000779	0.00709	CbGeAlD
Ruxolitinib—HIPK2—lung—esophageal cancer	0.000776	0.00707	CbGeAlD
Ruxolitinib—JAK2—bronchus—esophageal cancer	0.000775	0.00706	CbGeAlD
Ruxolitinib—TYK2—trachea—esophageal cancer	0.000765	0.00697	CbGeAlD
Ruxolitinib—MAP3K19—lung—esophageal cancer	0.00076	0.00692	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—esophageal cancer	0.000758	0.00691	CbGeAlD
Ruxolitinib—MKNK2—trachea—esophageal cancer	0.000755	0.00687	CbGeAlD
Ruxolitinib—MAP3K3—bronchus—esophageal cancer	0.000747	0.0068	CbGeAlD
Ruxolitinib—DAPK3—lung—esophageal cancer	0.000745	0.00679	CbGeAlD
Ruxolitinib—CAMK2G—digestive system—esophageal cancer	0.000745	0.00678	CbGeAlD
Ruxolitinib—PLK3—lymph node—esophageal cancer	0.000741	0.00675	CbGeAlD
Ruxolitinib—CLK2—lung—esophageal cancer	0.000738	0.00673	CbGeAlD
Ruxolitinib—ROCK1—lung—esophageal cancer	0.000716	0.00652	CbGeAlD
Ruxolitinib—LTK—lymph node—esophageal cancer	0.000715	0.00652	CbGeAlD
Ruxolitinib—DYRK1A—lung—esophageal cancer	0.000698	0.00636	CbGeAlD
Ruxolitinib—JAK2—trachea—esophageal cancer	0.000696	0.00634	CbGeAlD
Ruxolitinib—BMPR2—lung—esophageal cancer	0.000695	0.00633	CbGeAlD
Ruxolitinib—CAMK1—lymph node—esophageal cancer	0.000693	0.00631	CbGeAlD
Ruxolitinib—TAOK3—bronchus—esophageal cancer	0.000681	0.0062	CbGeAlD
Ruxolitinib—MARK2—lymph node—esophageal cancer	0.000673	0.00613	CbGeAlD
Ruxolitinib—MAP3K3—trachea—esophageal cancer	0.000671	0.00611	CbGeAlD
Ruxolitinib—NUAK2—lung—esophageal cancer	0.000664	0.00605	CbGeAlD
Ruxolitinib—TYK2—digestive system—esophageal cancer	0.000658	0.00599	CbGeAlD
Ruxolitinib—MKNK2—digestive system—esophageal cancer	0.000649	0.00591	CbGeAlD
Ruxolitinib—RET—digestive system—esophageal cancer	0.000633	0.00577	CbGeAlD
Ruxolitinib—TAOK2—lymph node—esophageal cancer	0.000622	0.00567	CbGeAlD
Ruxolitinib—CAMK2G—lung—esophageal cancer	0.000622	0.00567	CbGeAlD
Ruxolitinib—BMP2K—lung—esophageal cancer	0.000622	0.00567	CbGeAlD
Ruxolitinib—LRRK2—lung—esophageal cancer	0.000616	0.00562	CbGeAlD
Ruxolitinib—TAOK3—trachea—esophageal cancer	0.000611	0.00557	CbGeAlD
Ruxolitinib—JAK2—digestive system—esophageal cancer	0.000599	0.00545	CbGeAlD
Ruxolitinib—Myelosuppression—Cisplatin—esophageal cancer	0.000597	0.0727	CcSEcCtD
Ruxolitinib—JAK3—lymph node—esophageal cancer	0.000572	0.00521	CbGeAlD
Ruxolitinib—DCLK1—lymph node—esophageal cancer	0.000568	0.00518	CbGeAlD
Ruxolitinib—JAK1—lymph node—esophageal cancer	0.000568	0.00518	CbGeAlD
Ruxolitinib—MAP3K2—lung—esophageal cancer	0.000565	0.00515	CbGeAlD
Ruxolitinib—PLK4—lymph node—esophageal cancer	0.000565	0.00514	CbGeAlD
Ruxolitinib—MAP3K7—lung—esophageal cancer	0.00056	0.0051	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—esophageal cancer	0.000555	0.00505	CbGeAlD
Ruxolitinib—PHKG2—lymph node—esophageal cancer	0.000551	0.00502	CbGeAlD
Ruxolitinib—TYK2—lung—esophageal cancer	0.000549	0.005	CbGeAlD
Ruxolitinib—IRAK1—lung—esophageal cancer	0.000542	0.00494	CbGeAlD
Ruxolitinib—MKNK2—lung—esophageal cancer	0.000542	0.00494	CbGeAlD
Ruxolitinib—DAPK2—lymph node—esophageal cancer	0.000542	0.00494	CbGeAlD
Ruxolitinib—STK16—lymph node—esophageal cancer	0.000533	0.00486	CbGeAlD
Ruxolitinib—HIPK2—lymph node—esophageal cancer	0.000531	0.00483	CbGeAlD
Ruxolitinib—TAOK3—digestive system—esophageal cancer	0.000526	0.00479	CbGeAlD
Ruxolitinib—DAPK3—lymph node—esophageal cancer	0.00051	0.00464	CbGeAlD
Ruxolitinib—CLK2—lymph node—esophageal cancer	0.000505	0.0046	CbGeAlD
Ruxolitinib—JAK2—lung—esophageal cancer	0.0005	0.00455	CbGeAlD
Ruxolitinib—MAP3K3—lung—esophageal cancer	0.000482	0.00439	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—esophageal cancer	0.000477	0.00435	CbGeAlD
Ruxolitinib—BMPR2—lymph node—esophageal cancer	0.000475	0.00433	CbGeAlD
Ruxolitinib—NUAK2—lymph node—esophageal cancer	0.000454	0.00414	CbGeAlD
Ruxolitinib—TAOK3—lung—esophageal cancer	0.000439	0.004	CbGeAlD
Ruxolitinib—BMP2K—lymph node—esophageal cancer	0.000425	0.00388	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—esophageal cancer	0.000425	0.00388	CbGeAlD
Ruxolitinib—LRRK2—lymph node—esophageal cancer	0.000422	0.00384	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—esophageal cancer	0.000386	0.00352	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—esophageal cancer	0.000383	0.00349	CbGeAlD
Ruxolitinib—Night sweats—Capecitabine—esophageal cancer	0.000382	0.0465	CcSEcCtD
Ruxolitinib—TYK2—lymph node—esophageal cancer	0.000376	0.00342	CbGeAlD
Ruxolitinib—IRAK1—lymph node—esophageal cancer	0.000371	0.00338	CbGeAlD
Ruxolitinib—MKNK2—lymph node—esophageal cancer	0.000371	0.00338	CbGeAlD
Ruxolitinib—RET—lymph node—esophageal cancer	0.000362	0.0033	CbGeAlD
Ruxolitinib—JAK2—lymph node—esophageal cancer	0.000342	0.00311	CbGeAlD
Ruxolitinib—Infection—Carboplatin—esophageal cancer	0.000338	0.0412	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—esophageal cancer	0.00033	0.003	CbGeAlD
Ruxolitinib—TAOK3—lymph node—esophageal cancer	0.0003	0.00274	CbGeAlD
Ruxolitinib—Herpes zoster—Capecitabine—esophageal cancer	0.000274	0.0334	CcSEcCtD
Ruxolitinib—Body temperature increased—Carboplatin—esophageal cancer	0.000269	0.0328	CcSEcCtD
Ruxolitinib—Contusion—Capecitabine—esophageal cancer	0.000237	0.0288	CcSEcCtD
Ruxolitinib—Bone pain—Capecitabine—esophageal cancer	0.000215	0.0262	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—esophageal cancer	0.000204	0.0248	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000203	0.0247	CcSEcCtD
Ruxolitinib—Pancytopenia—Cisplatin—esophageal cancer	0.000167	0.0203	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—esophageal cancer	0.00016	0.00146	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00015	0.0182	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000148	0.018	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000132	0.0161	CcSEcCtD
Ruxolitinib—Pancytopenia—Capecitabine—esophageal cancer	0.000123	0.015	CcSEcCtD
Ruxolitinib—Malnutrition—Cisplatin—esophageal cancer	0.000122	0.0149	CcSEcCtD
Ruxolitinib—Neutropenia—Capecitabine—esophageal cancer	0.000121	0.0147	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—esophageal cancer	0.000121	0.0147	CcSEcCtD
Ruxolitinib—Weight increased—Capecitabine—esophageal cancer	0.000118	0.0143	CcSEcCtD
Ruxolitinib—Weight decreased—Capecitabine—esophageal cancer	0.000117	0.0143	CcSEcCtD
Ruxolitinib—Infestation—Capecitabine—esophageal cancer	0.000115	0.014	CcSEcCtD
Ruxolitinib—Infestation NOS—Capecitabine—esophageal cancer	0.000115	0.014	CcSEcCtD
Ruxolitinib—Anaemia—Cisplatin—esophageal cancer	0.000113	0.0138	CcSEcCtD
Ruxolitinib—Urinary tract infection—Capecitabine—esophageal cancer	0.000112	0.0137	CcSEcCtD
Ruxolitinib—Haematuria—Capecitabine—esophageal cancer	0.00011	0.0134	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000109	0.0133	CcSEcCtD
Ruxolitinib—Epistaxis—Capecitabine—esophageal cancer	0.000109	0.0133	CcSEcCtD
Ruxolitinib—Haemoglobin—Capecitabine—esophageal cancer	0.000104	0.0127	CcSEcCtD
Ruxolitinib—Haemorrhage—Capecitabine—esophageal cancer	0.000104	0.0126	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000103	0.0126	CcSEcCtD
Ruxolitinib—Infection—Cisplatin—esophageal cancer	9.92e-05	0.0121	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—esophageal cancer	9.79e-05	0.0119	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—esophageal cancer	9.78e-05	0.0119	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—esophageal cancer	9.7e-05	0.0118	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—esophageal cancer	9.15e-05	0.0111	CcSEcCtD
Ruxolitinib—Malnutrition—Capecitabine—esophageal cancer	9.02e-05	0.011	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—esophageal cancer	9.01e-05	0.011	CcSEcCtD
Ruxolitinib—Flatulence—Capecitabine—esophageal cancer	8.89e-05	0.0108	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	8.62e-05	0.0105	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—esophageal cancer	8.59e-05	0.0105	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—esophageal cancer	8.59e-05	0.0105	CcSEcCtD
Ruxolitinib—Anaemia—Capecitabine—esophageal cancer	8.34e-05	0.0101	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—esophageal cancer	8.19e-05	0.00997	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—esophageal cancer	8.13e-05	0.00989	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—esophageal cancer	8.11e-05	0.00986	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—esophageal cancer	7.9e-05	0.00961	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—esophageal cancer	7.75e-05	0.00944	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—esophageal cancer	7.71e-05	0.00939	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	7.63e-05	0.00928	CcSEcCtD
Ruxolitinib—Infection—Capecitabine—esophageal cancer	7.31e-05	0.0089	CcSEcCtD
Ruxolitinib—Nervous system disorder—Capecitabine—esophageal cancer	7.22e-05	0.00879	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Capecitabine—esophageal cancer	7.21e-05	0.00877	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—esophageal cancer	7.17e-05	0.00872	CcSEcCtD
Ruxolitinib—Skin disorder—Capecitabine—esophageal cancer	7.15e-05	0.0087	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—esophageal cancer	6.72e-05	0.00817	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	6.36e-05	0.00774	CcSEcCtD
Ruxolitinib—Fatigue—Capecitabine—esophageal cancer	6.35e-05	0.00773	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—esophageal cancer	6.21e-05	0.00755	CcSEcCtD
Ruxolitinib—Body temperature increased—Capecitabine—esophageal cancer	5.82e-05	0.00708	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	5.68e-05	0.00691	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—esophageal cancer	5.44e-05	0.00663	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—esophageal cancer	5.37e-05	0.00654	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—esophageal cancer	5.37e-05	0.00653	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—esophageal cancer	5.32e-05	0.00648	CcSEcCtD
Ruxolitinib—Asthenia—Capecitabine—esophageal cancer	5.28e-05	0.00643	CcSEcCtD
Ruxolitinib—Pruritus—Capecitabine—esophageal cancer	5.21e-05	0.00634	CcSEcCtD
Ruxolitinib—Dizziness—Capecitabine—esophageal cancer	4.87e-05	0.00593	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	4.73e-05	0.00576	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—esophageal cancer	4.73e-05	0.00575	CcSEcCtD
Ruxolitinib—Headache—Capecitabine—esophageal cancer	4.61e-05	0.00561	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—esophageal cancer	4.33e-05	0.00527	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—esophageal cancer	3.93e-05	0.00479	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—esophageal cancer	3.88e-05	0.00472	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—esophageal cancer	3.62e-05	0.00441	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—esophageal cancer	3.43e-05	0.00418	CcSEcCtD
Ruxolitinib—IRAK1—Immune System—CREBBP—esophageal cancer	4.93e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—PIK3CA—esophageal cancer	4.93e-06	2.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS2—esophageal cancer	4.92e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ANXA1—esophageal cancer	4.92e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—esophageal cancer	4.92e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KDR—esophageal cancer	4.91e-06	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—esophageal cancer	4.9e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MYC—esophageal cancer	4.89e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFBR2—esophageal cancer	4.89e-06	2.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOTCH1—esophageal cancer	4.88e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CREBBP—esophageal cancer	4.87e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB2—esophageal cancer	4.84e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KDR—esophageal cancer	4.83e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CASP8—esophageal cancer	4.81e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EP300—esophageal cancer	4.8e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—esophageal cancer	4.79e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—esophageal cancer	4.79e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CREBBP—esophageal cancer	4.79e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—esophageal cancer	4.79e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SST—esophageal cancer	4.78e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—esophageal cancer	4.77e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMAD4—esophageal cancer	4.77e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—esophageal cancer	4.75e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFBR2—esophageal cancer	4.75e-06	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—EP300—esophageal cancer	4.71e-06	2.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CASP8—esophageal cancer	4.67e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH3—esophageal cancer	4.66e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GHRL—esophageal cancer	4.66e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CREBBP—esophageal cancer	4.64e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CDKN1A—esophageal cancer	4.64e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—esophageal cancer	4.64e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMAD4—esophageal cancer	4.63e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—esophageal cancer	4.63e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOTCH1—esophageal cancer	4.63e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FBXW7—esophageal cancer	4.59e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—PIK3CA—esophageal cancer	4.58e-06	2.28e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOTCH1—esophageal cancer	4.55e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—PIK3CA—esophageal cancer	4.5e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMAD4—esophageal cancer	4.49e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—PIK3CA—esophageal cancer	4.48e-06	2.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CDKN1A—esophageal cancer	4.46e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—esophageal cancer	4.44e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CREBBP—esophageal cancer	4.42e-06	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EP300—esophageal cancer	4.42e-06	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—esophageal cancer	4.38e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOS3—esophageal cancer	4.36e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—esophageal cancer	4.34e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CDKN1A—esophageal cancer	4.29e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—esophageal cancer	4.27e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—PIK3CA—esophageal cancer	4.27e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BLVRB—esophageal cancer	4.26e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC52A3—esophageal cancer	4.26e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL2—esophageal cancer	4.25e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—TLR4—esophageal cancer	4.25e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EP300—esophageal cancer	4.24e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CREBBP—esophageal cancer	4.19e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH2—esophageal cancer	4.18e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—PIK3CA—esophageal cancer	4.16e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PIK3CA—esophageal cancer	4.16e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—PIK3CA—esophageal cancer	4.14e-06	2.07e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CDKN1A—esophageal cancer	4.13e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB2—esophageal cancer	4.13e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL2—esophageal cancer	4.13e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CREBBP—esophageal cancer	4.12e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—PIK3CA—esophageal cancer	4.12e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—esophageal cancer	4.12e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HIF1A—esophageal cancer	4.1e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—esophageal cancer	4.1e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB2—esophageal cancer	4.08e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EP300—esophageal cancer	4.08e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—esophageal cancer	4.05e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—PIK3CA—esophageal cancer	4.03e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—PIK3CA—esophageal cancer	4.02e-06	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB2—esophageal cancer	4.01e-06	2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2—esophageal cancer	4e-06	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS3—esophageal cancer	3.96e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.94e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EP300—esophageal cancer	3.93e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HIF1A—esophageal cancer	3.9e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—esophageal cancer	3.89e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.87e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—PIK3CA—esophageal cancer	3.86e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PIK3CA—esophageal cancer	3.8e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HIF1A—esophageal cancer	3.79e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—esophageal cancer	3.76e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOS3—esophageal cancer	3.75e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KDR—esophageal cancer	3.73e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS2—esophageal cancer	3.73e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFBR2—esophageal cancer	3.71e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—esophageal cancer	3.7e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOTCH1—esophageal cancer	3.7e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOS3—esophageal cancer	3.69e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HIF1A—esophageal cancer	3.68e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP8—esophageal cancer	3.65e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CREBBP—esophageal cancer	3.63e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KDR—esophageal cancer	3.62e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—esophageal cancer	3.62e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA1—esophageal cancer	3.62e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.62e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—esophageal cancer	3.62e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—esophageal cancer	3.61e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PIK3CA—esophageal cancer	3.58e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—esophageal cancer	3.55e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDKN1A—esophageal cancer	3.53e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—esophageal cancer	3.52e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH1—esophageal cancer	3.52e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KDR—esophageal cancer	3.52e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—esophageal cancer	3.51e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMAD4—esophageal cancer	3.51e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN1A—esophageal cancer	3.49e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—esophageal cancer	3.49e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—esophageal cancer	3.48e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—esophageal cancer	3.45e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—esophageal cancer	3.43e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDKN1A—esophageal cancer	3.43e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH1—esophageal cancer	3.41e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—esophageal cancer	3.37e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—esophageal cancer	3.36e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—esophageal cancer	3.35e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CREBBP—esophageal cancer	3.35e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1A—esophageal cancer	3.32e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—esophageal cancer	3.32e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH1—esophageal cancer	3.31e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA2—esophageal cancer	3.31e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—esophageal cancer	3.27e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—esophageal cancer	3.26e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CREBBP—esophageal cancer	3.19e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1A—esophageal cancer	3.16e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—esophageal cancer	3.16e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—esophageal cancer	3.14e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—esophageal cancer	3.13e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—esophageal cancer	3.1e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CREBBP—esophageal cancer	3.1e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADH7—esophageal cancer	3.08e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.08e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—esophageal cancer	3.05e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—esophageal cancer	3.04e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—esophageal cancer	3.04e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—esophageal cancer	3.02e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—esophageal cancer	3.01e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CREBBP—esophageal cancer	3e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1A—esophageal cancer	3e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—esophageal cancer	3e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1A—esophageal cancer	2.95e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—esophageal cancer	2.91e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—esophageal cancer	2.89e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—esophageal cancer	2.87e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—esophageal cancer	2.86e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—esophageal cancer	2.86e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—esophageal cancer	2.86e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—esophageal cancer	2.83e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—esophageal cancer	2.82e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—esophageal cancer	2.81e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—esophageal cancer	2.81e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—esophageal cancer	2.78e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—esophageal cancer	2.77e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—esophageal cancer	2.75e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—esophageal cancer	2.74e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.7e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—esophageal cancer	2.7e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—esophageal cancer	2.69e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—esophageal cancer	2.67e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—esophageal cancer	2.64e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—esophageal cancer	2.62e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—esophageal cancer	2.6e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—esophageal cancer	2.59e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—esophageal cancer	2.59e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMP—esophageal cancer	2.58e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—esophageal cancer	2.57e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—esophageal cancer	2.51e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.51e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—esophageal cancer	2.49e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—esophageal cancer	2.48e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—esophageal cancer	2.47e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—esophageal cancer	2.46e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—esophageal cancer	2.45e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.44e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—esophageal cancer	2.43e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—esophageal cancer	2.41e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—esophageal cancer	2.4e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—esophageal cancer	2.39e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—esophageal cancer	2.38e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	2.36e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREBBP—esophageal cancer	2.35e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—esophageal cancer	2.34e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TPI1—esophageal cancer	2.33e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.33e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—esophageal cancer	2.31e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—esophageal cancer	2.29e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	2.28e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—esophageal cancer	2.28e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.24e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—esophageal cancer	2.23e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—esophageal cancer	2.22e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—esophageal cancer	2.22e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.2e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	2.17e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.15e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—esophageal cancer	2.15e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.13e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—esophageal cancer	2.11e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—esophageal cancer	2.11e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—esophageal cancer	2.11e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—esophageal cancer	2.1e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—esophageal cancer	2.08e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—esophageal cancer	2.04e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—esophageal cancer	2.04e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNG7—esophageal cancer	2.03e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—esophageal cancer	2.01e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—esophageal cancer	2e-06	9.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—esophageal cancer	1.99e-06	9.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—esophageal cancer	1.96e-06	9.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—esophageal cancer	1.94e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.9e-06	9.48e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	1.89e-06	9.44e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	1.85e-06	9.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—esophageal cancer	1.84e-06	9.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—esophageal cancer	1.83e-06	9.12e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.81e-06	9.02e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—esophageal cancer	1.8e-06	8.96e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.79e-06	8.91e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—esophageal cancer	1.78e-06	8.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—esophageal cancer	1.74e-06	8.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—esophageal cancer	1.74e-06	8.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.69e-06	8.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.69e-06	8.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—esophageal cancer	1.69e-06	8.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—esophageal cancer	1.68e-06	8.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.67e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.67e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	1.61e-06	8.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—esophageal cancer	1.6e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—esophageal cancer	1.56e-06	7.78e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	1.55e-06	7.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—esophageal cancer	1.51e-06	7.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—esophageal cancer	1.51e-06	7.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—esophageal cancer	1.46e-06	7.3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.44e-06	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—esophageal cancer	1.39e-06	6.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—esophageal cancer	1.36e-06	6.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.35e-06	6.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.24e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.19e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—esophageal cancer	1.18e-06	5.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—esophageal cancer	1.14e-06	5.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.93e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—esophageal cancer	7.1e-07	3.54e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.49e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—esophageal cancer	5.4e-07	2.69e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4e-07	1.99e-06	CbGpPWpGaD
